Related Experiment Video
Updated: Aug 20, 2026

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
Published on: December 4, 2018
Report of two novel chromosomal translocations in chronic lymphocytic leukemia
A Athanasiadou1, K Stamatopoulos, A Tsompanakou
1Hematology Department and BMT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece. stavstam@otenet.gr
Insights
Two novel chromosomal translocations were identified in patients with chronic lymphocytic leukemia (CLL). These findings contribute to understanding genetic alterations in CLL progression.
Area of Science:
- Hematology
- Cytogenetics
- Oncology
Background:
- Chronic lymphocytic leukemia (CLL) is a heterogeneous lymphoid malignancy.
- Chromosomal abnormalities play a crucial role in CLL pathogenesis and prognosis.
- Identifying novel genetic alterations can improve our understanding of CLL biology.
Observation:
- Two distinct cases of CLL presented with novel chromosomal translocations.
- Case 1 involved a t(9;12)(q12;p11) translocation in a Rai 0/Binet A patient with mutated IgH and Iglambda genes.
- Case 2 involved an add(10)(q26) and t(13;18)(q14;q21) in a Rai 2/Binet B patient with mutated IgH and unmutated Iglambda genes.
Findings:
- The identified translocations, t(9;12)(q12;p11) and t(13;18)(q14;q21), are novel in CLL.
- Breakpoints at 13q14 and 18q21, seen in Case 2, are known to be involved in other CLL aberrations.
- Aberrations involving 9q12 and 12p11, as in Case 1, are infrequently reported in CLL.
Implications:
- These novel translocations expand the spectrum of known genetic aberrations in CLL.
- Further research into these specific translocations may reveal new insights into CLL development and progression.
- Understanding rare chromosomal abnormalities can refine prognostic models and guide therapeutic strategies in CLL.
Abstract:
Two novel chromosomal translocations were identified in 2 patients with chronic lymphocytic leukemia (CLL). Case 1: 60 year-old male, stage Rai 0/Binet A, with mutated immunoglobulin heavy (IgH) and lambda (Iglambda) light chain genes; karyotype: 46, XY, t(9;12)(q12;p11) [3]/ 46, XY [22]. Case 2: 56 year-old male, stage Rai 2/Binet B, with mutated IgH and unmutated Iglambda genes; karyotype: 46, XY, add(10)(q26), t(13;18)(q14;q21) [8]/ 46, XY [27]. Although both translocations are novel, the involved breakpoints (especially 13q14 and 18q21) have been reported to participate in various aberrations in CLL patients. Aberrations affecting bands 9q12 and 12p11, as in case 1, are generally rare.
Related Concept Videos
Non-LTR Retrotransposons
Overview of Transposition and Recombination

